2-amino-6-methyl-4-propyl-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

test procedure in accordance with national standard methods with acceptable restrictions

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1970

Report date:

1970

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

Ten albino mice per sex/dose were exposed intravenously to 75, 100, and 150 mg/kg test substance and observed for 14 days.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-amino-6-methyl-4-propyl-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one

EC Number:

248-383-5

EC Name:

2-amino-6-methyl-4-propyl-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one

Cas Number:

27277-00-5

Molecular formula:

C9H13N5O

IUPAC Name:

2-amino-6-methyl-4-propyl-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one

Test material form:

solid: particulate/powder

Test animals

Species:

mouse

Strain:

other: albino

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: between 18 and 22 g
- Housing: 10 to a cage
- Diet: standard pelleted diet, ad libitum
- Water: ad libitum

Administration / exposure

Route of administration:

intravenous

Vehicle:

other: nonylphenolethyleneoxide 0.1%, sodium salt of sulphated cetyl/oleyl alcohol mixture 0.1%, polyglyceryl ricinoleate 0.1 %, and water to 100 %

Details on exposure:

VEHICLE
The suspensions of 0.1 % (w/v), 0.025 % (w/v), and 0.005% (w/v) were prepared by ball milling the drug into a solution of nonylphenolethyleneoxide 0.1 %, sodium salt of sulphated cetyl/oleyl alcohol mixture 0.1 %, polyglyceryl ricinoleate 0.1 %, and water to 100 % .

MAXIMUM DOSE VOLUME APPLIED:
The administration volume was 0.2 mL.

MAXIMUM DOSE APPLIED: it was impossible to administer a larger dose than 150 mg/kg due to the insolubility of the compound.

Doses:

75, 100, and 150 mg/kg

No. of animals per sex per dose:

10

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 150 mg/kg bw

Based on:

test mat.

Mortality:

75 mg/kg: 0/20 animals died
100 mg/kg: 0/20 animals died
150 mg/kg: 8/20 animals died

The mice that died, did so within fifteen minutes of dosing.

Clinical signs:

Many of the animals receiving the compound developed a rapid rate of respiration immediately. The majority of the mice receiving 100 mg/kg and 150 mg/kg had convulsions within an hour after dosing, but recovered.

Gross pathology:

No gross abnormalities were observed at autopsy.

Applicant's summary and conclusion

Conclusions:

Under the conditions of the test it can be concluded that the acute intravenous LD50 for mice is >150 mg/kg bw.

Executive summary:

Ten albino mice per sex/dose were exposed intravenous to 75, 100, and 150 mg/kg test substance and observed for 14 days. 0/20, 0/20, and 8/20 animals died after dosing 75, 100, and 150 mg/kg test substance, respectively. It was impossible to administer a larger dose than 150 mg/kg due to the insolubility of the compound. Under the conditions of the test it can be concluded that the acute LD50 for mice is >150 mg/kg bw.